Skin and Soft Tissue Infections

KALYANAKRISHNAN RAMAKRISHNAN, MD; ROBERT C. SALINAS, MD; and NELSON IVAN AGUDELO HIGUITA, MD
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Skin and soft tissue infections result from microbial invasion of the skin and its supporting structures. Management is determined by the severity and location of the infection and by patient comorbidities. Infections can be classified as simple ( uncomplicated) or complicated (necrotizing or nonnecrotizing), or as suppurative or nonsuppurative. Most community-acquired infections are caused by methicillin-resistant *Staphylococcus aureus* and beta-hemolytic streptococcus. Simple infections are usually monomicrobial and present with localized clinical findings. In contrast, complicated infections can be mono- or polymicrobial and may present with systemic inflammatory response syndrome. The diagnosis is based on clinical evaluation. Laboratory testing may be required to confirm an uncertain diagnosis, evaluate for deep infections or sepsis, determine the need for inpatient care, and evaluate and treat comorbidities. Initial antimicrobial choice is empiric, and in simple infections should cover *Staphylococcus* and *Streptococcus* species. Patients with complicated infections, including suspected necrotizing fascitis and gangrene, require empiric polymicrobial antibiotic coverage, inpatient treatment, and surgical consultation for debridement. Superficial and small abscesses respond well to drainage and seldom require antibiotics. Immunocompromised patients require early treatment and antimicrobial coverage for possible atypical organisms. (Am Fam Physician. 2015;92(6):474-483. Copyright © 2015 American Academy of Family Physicians.)

Skin and soft tissue infections (SSTIs) account for more than 14 million physician office visits each year in the United States, as well as emergency department visits and hospitalizations. The greatest incidence is among persons 18 to 44 years of age, men, and blacks. Community-acquired methicillin-resistant *Staphylococcus aureus* (MRSA) accounts for 59% of SSTIs presenting to the emergency department.

**Classification**

SSTIs are classified as simple ( uncomplicated) or complicated (necrotizing or nonnecrotizing) and can involve the skin, subcutaneous fat, fascial layers, and musculotendinous structures. SSTIs can be purulent or nonpurulent (mild, moderate, or severe). To help stratify clinical interventions, SSTIs can be classified based on their severity, presence of comorbidities, and need for and nature of therapeutic intervention.

Simple infections confined to the skin and underlying superficial soft tissues generally respond well to outpatient management. Common simple SSTIs include cellulitis, erysipelas, impetigo, ecthyma, folliculitis, furuncles, carbuncles, abscesses, and trauma-related infections ( Figures 1 through 3). Complicated infections extending into and involving the underlying deep tissues include deep abscesses, decubitus ulcers, necrotizing fascitis, Fournier gangrene, and infections from human or animal bites ( Figure 4). These infections may present with features of systemic inflammatory response syndrome or sepsis, and, occasionally, ischemic necrosis. Perianal infections, diabetic foot infections, infections in patients with significant comorbidities, and infections from resistant pathogens also represent complicated infections.

**Risk Factors**

Older age, cardiopulmonary or hepatorenal disease, diabetes mellitus, debility, immunosenescence or immunocompromise, obesity, peripheral arteriovenous or lymphatic insufficiency, and trauma are among the risk factors for SSTIs ( Table 2). Outbreaks are more common among military personnel during overseas deployment and athletes participating in close-contact sports. Community-acquired MRSA causes infection in a wide variety of hosts, from healthy children and young adults to persons with comorbidities, health care professionals, and persons living in close quarters.
Skin and Soft Tissue Infections

Predisposing factors for SSTIs include reduced tissue vascularity and oxygenation, increased peripheral fluid stasis and risk of skin trauma, and decreased ability to combat infections. For example, diabetes increases the risk of infection-associated complications fivefold. Comorbidities and mechanisms of injury can determine the bacteriology of SSTIs (Table 3). For instance,

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Simple infection with no systemic signs or symptoms indicating spread* and no uncontrolled comorbidities that may complicate treatment; amenable to outpatient management with topical or oral antimicrobials</td>
</tr>
<tr>
<td>2</td>
<td>Infection with systemic signs or symptoms indicating spread* or with stable comorbidities, or infection without systemic spread but with uncontrolled comorbidities; may require inpatient management or parenteral antibiotics</td>
</tr>
<tr>
<td>3</td>
<td>Infection with signs or symptoms of systemic spread* or uncontrolled comorbidities; inpatient management with parenteral antibiotics required</td>
</tr>
<tr>
<td>4</td>
<td>Infection with signs of potentially fatal systemic sepsis† requiring parenteral antibiotics; inpatient management (possibly in critical care unit) required, surgery may be indicated</td>
</tr>
</tbody>
</table>

*—Signs and symptoms indicating spread of infection: fever, tachycardia, diaphoresis, fatigue, anorexia, and vomiting.
†—Signs indicating systemic sepsis: mental status changes, tachycardia, tachypnea, and hypotension.

Information from reference 3.

**Table 1. Classification System for Skin and Soft Tissue Infections**

**Figure 1.** Cellulitis anterior to abdominal wall.

**Figure 2.** Abscess over left gluteal region.

**Figure 3.** Furuncle.

**Figure 4.** Pyoderma gangrenosum.
### Table 2. Risk Factors for Skin and Soft Tissue Infections

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (children, older adults)</td>
<td>Obese</td>
</tr>
<tr>
<td>Alcohol abuse†</td>
<td>Peripheral arteriovenous insufficiency</td>
</tr>
<tr>
<td>Asplenia</td>
<td>Peripheral neuropathy</td>
</tr>
<tr>
<td>Cardiopulmonary disease</td>
<td>Poor nutrition‡</td>
</tr>
<tr>
<td>Debility</td>
<td>Prolonged hospitalization‡</td>
</tr>
<tr>
<td>Diabetes mellitus†‡</td>
<td>Sports participation‡</td>
</tr>
<tr>
<td>Dialysis (peritoneal, hemodialysis)†</td>
<td>Subcutaneous or intravenous drug use</td>
</tr>
<tr>
<td>Health care professional*</td>
<td>Trauma (including surgery)†</td>
</tr>
<tr>
<td>Hepatorenal disease</td>
<td>Water exposure (e.g., ocean, hot tubs)</td>
</tr>
</tbody>
</table>

*—Risk factor for community-acquired methicillin-resistant Staphylococcus aureus infection.
†—Also predisposes to necrotizing fasciitis.
‡—Risk factor for hospital-acquired methicillin-resistant S. aureus infection.

Information from references 9 through 11.

### Table 3. Bacteriology and Clinical Features of Skin and Soft Tissue Infections

<table>
<thead>
<tr>
<th>Infection</th>
<th>Microbiology</th>
<th>Clinical features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abscess</td>
<td>Staphylococcus aureus, Streptococcus, anaerobes (often polymicrobial)</td>
<td>Collection of pus with surrounding granulation; painful swelling with induration and central fluctuance; possible overlying skin necrosis; signs or symptoms of infection*; features attenuated in cold abscess; recurrent abscesses with sinus tracts and scarring in axillae and groin occur in hidradenitis suppurativa</td>
</tr>
<tr>
<td>Bites (human, animal)</td>
<td>Polymicrobial (Bacteroides, Bartonella henselae, Capnocytophaga canimorsus, Eikenella corrodens, Pasteurella multocida, Peptostreptococcus, S. aureus, Streptobacillus moniliformis)</td>
<td>Cat bites become infected more often than dog or human bites (30% to 50%, up to 20%, and 10% to 50%, respectively); infection sets in 8 to 12 hours after animal bites; human bites may transmit herpes, hepatitis, or human immunodeficiency virus; may involve tendons, tendon sheaths, bone, and joints</td>
</tr>
<tr>
<td>Clostridial myonecrosis (gas gangrene)</td>
<td>Clostridium (usually C. perfringens, C. septicum)</td>
<td>Traumatic or spontaneous; severe pain at injury site followed by skin changes (e.g., pale, bronze, purplish red), tenderness, induration, blistering, and tissue crepitus; diaphoresis, fever, hypotension, and tachycardia</td>
</tr>
<tr>
<td>Erysipelas, cellulitis</td>
<td>Beta-hemolytic streptococci, Haemophilus influenzae (children), S. aureus</td>
<td>Erysipelas: usually over face, ears, or lower legs; distinctly raised inflamed skin Cellulitis: over areas of skin breakdown</td>
</tr>
<tr>
<td>Folliculitis</td>
<td>Candida, dermatophytes, Pseudomonas aeruginosa, S. aureus</td>
<td>Infection or inflammation of the hair follicles; tends to occur in areas with increased sweating; associated with acne or steroid use; painful or painless pustule with underlying swelling</td>
</tr>
<tr>
<td>Fournier gangrene</td>
<td>Polymicrobial</td>
<td>Genital, groin, or perineal involvement; cellulitis, and signs or symptoms of infection* followed by suppurration and necrosis of overlying skin</td>
</tr>
<tr>
<td>Furuncle, carbuncle (deep folliculitis)</td>
<td>S. aureus</td>
<td>Walled-off collection of pus; painful, firm swelling; systemic features of infection; carbuncles are larger, deeper, and involve skin and subcutaneous tissue over thicker skin of neck, back, and lateral thighs, and drain through multiple pores</td>
</tr>
<tr>
<td>Impetigo (non-bullous, bullous)</td>
<td>Beta-hemolytic streptococci, S. aureus</td>
<td>Common in infants and children; affects skin of nose, mouth, or limbs; mild soreness, redness, vesicles, and crusting; may cause glomerulonephritis; vesicles may enlarge (bullae); may spread to lymph nodes, bone, joints, or lung</td>
</tr>
<tr>
<td>Necrotizing fasciitis</td>
<td>Type 1: polymicrobial</td>
<td>Spreading infection of subcutaneous tissue; usually affects genitalia, perineum, or lower extremities; severe, constant pain; signs or symptoms of infection*; overlying redness and cutaneous anesthesia; edema and induration of apparently uninvolved tissues; skin crepitus; progression despite antibiotics</td>
</tr>
<tr>
<td></td>
<td>Type 2: monomicrobial</td>
<td></td>
</tr>
</tbody>
</table>

*—Signs and symptoms of infection include fever, tachycardia, diaphoresis, fatigue, anorexia, nausea, and vomiting. Mental status changes and hypotension suggest worsening sepsis and hemodynamic compromise.

Information from references 5 and 15.
Skin and Soft Tissue Infections

Pseudomonas aeruginosa infections are associated with intravenous drug use and hot tub use, and patients with neutropenia more often develop infections caused by gram-negative bacteria, anaerobes, and fungi.

Pathogenesis

Most SSTIs occur de novo, or follow a breach in the protective skin barrier from trauma, surgery, or increased tissue tension secondary to fluid stasis. The infection may also originate from an adjacent site or from embolic spread from a distant site. S. aureus and streptococci are responsible for most simple community-acquired SSTIs. In one prospective study, beta-hemolytic streptococcus was found to cause nearly three-fourths of cases of diffuse cellulitis. S. aureus, P. aeruginosa, enterococcus, and Escherichia coli are the predominant organisms isolated from hospitalized patients with SSTIs. MRSA infections are characterized by liquefaction of infected tissue and abscess formation; the resulting increase in tissue tension causes ischemia and overlying skin necrosis. Lymphatic and hematogenous dissemination causes septicemia and spread to other organs (e.g., lung, bone, heart valves). Diabetic lower limb infections, severe hospital-acquired infections, necrotizing infections, and head and hand infections pose higher risks of mortality and functional disability.

Clinical Presentation

Patients with simple SSTIs present with erythema, warmth, edema, and pain over the affected site. Systemic features of infection may follow, their intensity reflecting the magnitude of infection. The lower extremities are most commonly involved. Induration is characteristic of more superficial infections such as erysipelas and cellulitis. Patients with necrotizing fasciitis may have pain disproportionate to the physical findings, rapid progression of infection, cutaneous anesthesia, hemorrhage or bullous changes, and crepitus indicating gas in the soft tissues. Tense overlying edema and bullae, when present, help distinguish necrotizing fasciitis from non-necrotizing infections.

Diagnosis

The diagnosis of SSTIs is predominantly clinical. A complete blood count, C-reactive protein level, and liver and kidney function tests should be ordered for patients with severe infections, and for those with comorbidities causing organ dysfunction. The Laboratory Risk Indicator for Necrotizing Fasciitis score uses laboratory parameters to stratify patients into high- and low-risk categories for necrotizing fasciitis (Table 4); a score of 6 or higher is indicative, whereas a score of 8 or higher is strongly predictive (positive predictive value = 93.4%).

Blood cultures are unlikely to change the management of simple localized SSTIs in otherwise healthy, immunocompetent patients, and are typically unnecessary. However, because of the potential for deep tissue involvement, cultures are useful in patients with severe infections or signs of systemic involvement, in older or immunocompromised patients, and in patients requiring surgery. Wound cultures are not indicated in most healthy patients, including those with suspected MRSA infection, but are useful in immunocompromised patients and those with significant cellulitis; lymphangitis; sepsis; recurrent, persistent, or large abscesses; or infections from human or animal bites. Tissue biopsies, which are the preferred diagnostic test for necrotizing SSTIs, are ideally taken from the advancing margin...

Table 4. Laboratory Risk Indicator for Necrotizing Fasciitis

<table>
<thead>
<tr>
<th>Laboratory value</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>C-reactive protein</td>
<td></td>
</tr>
<tr>
<td>&lt; 150 mg per L (&lt;1,430 nmol per L)</td>
<td>0</td>
</tr>
<tr>
<td>≥ 150 mg per L</td>
<td>4</td>
</tr>
<tr>
<td>Creatinine</td>
<td></td>
</tr>
<tr>
<td>≤ 1.6 mg per dL (&lt;141 µmol per L)</td>
<td>0</td>
</tr>
<tr>
<td>&gt; 1.6 mg per dL</td>
<td>2</td>
</tr>
<tr>
<td>Glucose</td>
<td></td>
</tr>
<tr>
<td>≤ 180 mg per dL (&lt;10 mmol per L)</td>
<td>0</td>
</tr>
<tr>
<td>&gt; 180 mg per dL</td>
<td>1</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td></td>
</tr>
<tr>
<td>&gt; 13.5 g per dL (&gt;135 g per L)</td>
<td>0</td>
</tr>
<tr>
<td>11 to 13.5 g per dL (110 to 135 g per L)</td>
<td>1</td>
</tr>
<tr>
<td>&lt; 11 g per dL</td>
<td>2</td>
</tr>
<tr>
<td>Sodium</td>
<td></td>
</tr>
<tr>
<td>≥ 135 mEq per L (&gt;135 mmol per L)</td>
<td>0</td>
</tr>
<tr>
<td>&lt; 135 mEq per L</td>
<td>2</td>
</tr>
<tr>
<td>Total white blood cells</td>
<td></td>
</tr>
<tr>
<td>&lt; 15,000 per mm³ (&lt;15.0 × 10⁹ per L)</td>
<td>0</td>
</tr>
<tr>
<td>15,000 to 25,000 per mm³ (15.0 × 10⁹ to 25.0 × 10⁹ per L)</td>
<td>1</td>
</tr>
<tr>
<td>&gt; 25,000 per mm³</td>
<td>2</td>
</tr>
</tbody>
</table>

NOTE: Maximum score is 13. Scores of 6 or more are indicative of necrotizing fasciitis, and scores of 8 or more are highly predictive.

of the wound, from the depth of bite wounds, and after debridement of necrotizing infections and traumatic wounds. Sterile aspiration of infected tissue is another recommended sampling method, preferably before commencing antibiotic therapy.22 Imaging studies are not indicated for simple SSTIs, and surgery should not be delayed for imaging. Plain radiography, ultrasonography, computed tomography, or magnetic resonance imaging may show soft tissue edema or fascial thickening, fluid collections, or soft tissue air. Magnetic resonance imaging is highly sensitive (100%) for necrotizing fasciitis; specificity is lower (86%).24 Extensive involvement of the deep intermuscular fascia, fascial thickening (more than 3 mm), and partial or complete absence of signal enhancement of the thickened fasciae on postgadolinium images suggest necrotizing fasciitis.25 Adding ultrasonography to clinical examination in children and adolescents with clinically suspected SSTI increases the accuracy of diagnosing the extent and depth of infection (sensitivity = 77.6% vs. 43.7%; specificity = 61.3% vs. 42.0%, respectively).26

Management
The management of SSTIs is determined primarily by their severity and location, and by the patient’s comorbidities (Figure 5). According to guidelines from the American Family Physician, initial management of a patient with skin and soft tissue infection is as follows:

Figure 5. Initial management of skin and soft tissue infections. (MRSA = methicillin-resistant Staphylococcus aureus; MSSA = methicillin-sensitive S. aureus.)
Infectious Diseases Society of America, initial management is determined by the presence or absence of purulence, acuity, and type of infection.3

**MILD TO MODERATE INFECTIONS**

Topical antibiotics (e.g., mupirocin [Bactroban], retapamulin [Altabax]) are options in patients with impetigo and folliculitis (Table 5).5,27 Beta-lactams are effective in children with nonpurulent SSTIs, such as uncomplicated cellulitis or impetigo.28 In adults, mild to moderate SSTIs respond well to beta-lactams in the absence of suppuration.26 Patients who do not improve or who worsen after 48 hours of treatment should receive antibiotics to cover possible MRSA infection and imaging to detect purulence.16 Mild purulent SSTIs in easily accessible areas without significant overlying cellulitis can be treated with incision and drainage alone.29,30 In children, minimally invasive techniques (e.g., stab incision, hemostat rupture of septations, in-dwelling drain placement) are effective, reduce morbidity and hospital stay, and are more economical compared with traditional drainage and wound packing.31

Antibiotic therapy is required for abscesses that are associated with extensive cellulitis, rapid progression, or poor response to initial drainage; that involve specific sites (e.g., face, hands, genitalia); and that occur in children and older adults or in those who have significant comorbid illness or immunosuppression.32 In uncomplicated cellulitis, five days of treatment is as effective as 10 days.33 In a randomized controlled trial of 200 children with uncomplicated SSTIs primarily caused by MRSA, clindamycin and cephalexin (Keflex) were equally effective.34

**SEVERE INFECTIONS**

Inpatient treatment is necessary for patients who have uncontrolled infection despite adequate outpatient antimicrobial therapy or who cannot tolerate oral antibiotics (Figure 6). Hospitalization is also indicated for patients who initially present with severe or complicated infections, unstable comorbid illnesses, or signs of systemic sepsis, or who need surgical intervention under anesthesia.25 Broad-spectrum antibiotics with proven effectiveness against gram-positive and gram-negative organisms and anaerobes should be used until pathogen-specific sensitivities are available; coverage can then be narrowed. Intravenous antibiotics should be continued until the clinical

---

**Table 5. Antibiotic Choices for Mild to Moderate Skin and Soft Tissue Infections in Adults and Children**

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoxicillin/clavulanate (Augmentin)</td>
<td>For impetigo; human or animal bites; and MSSA, Escherichia coli, or Klebsiella infections</td>
</tr>
<tr>
<td>Cefazolin*</td>
<td>For MSSA infections and human or animal bites</td>
</tr>
<tr>
<td>Cephalexin (Keflex)</td>
<td>For MSSA infections, impetigo, and human or animal bites</td>
</tr>
<tr>
<td>Clindamycin*</td>
<td>For impetigo; MSSA, MRSA, and clostridial infections; and human or animal bites</td>
</tr>
<tr>
<td>Dicloxacillin</td>
<td>For MSSA infections</td>
</tr>
<tr>
<td>Doxycycline or minocycline (Minocin)</td>
<td>For MRSA infections and human or animal bites; not recommended for children younger than 8 years</td>
</tr>
<tr>
<td>Fluoroquinolones</td>
<td>For human or animal bites; not useful in MRSA infections; not recommended for children</td>
</tr>
<tr>
<td>Mupirocin (Bactroban)*</td>
<td>For MRSA impetigo and folliculitis; not recommended for children younger than 2 months</td>
</tr>
<tr>
<td>Retapamulin (Altabax)*</td>
<td>For MSSA impetigo; not recommended for children younger than 9 months</td>
</tr>
<tr>
<td>Trimethoprim/sulfamethoxazole</td>
<td>For MRSA infections and human or animal bites; contraindicated in children younger than 2 months</td>
</tr>
</tbody>
</table>

**NOTE:** This is a condensed version of this table. The full version is available online at http://www.aafp.org/afp.

MRSA = methicillin-resistant Staphylococcus aureus; MSSA = methicillin-sensitive S. aureus.

*—Higher dosages used in complicated infections caused by sensitive organisms. Information from references 5 and 27.
picture improves, the patient can tolerate oral intake, and drainage or debridement is completed. The recommended duration of antibiotic therapy for hospitalized patients is seven to 14 days. A Cochrane review did not establish the superiority of any one pathogen-sensitive antibiotic over another in the treatment of MRSA SSTI. Intravenous antibiotics may be continued at home under close supervision after initiation in the hospital or emergency department. Antibiotic choices for severe infections (including MRSA SSTI) are outlined in Table 6.

**Necrotizing Fasciitis.** Treatment of necrotizing fasciitis involves early recognition and surgical consultation for debridement of necrotic tissue combined with empiric high-dose intravenous broad-spectrum antibiotics. The antibiotic spectrum can be narrowed once the infecting microbes are identified and susceptibility testing results are available. Monomicrobial necrotizing fasciitis caused by streptococcal and clostridial infections is treated with penicillin G and clindamycin; *S. aureus* infections are treated according to susceptibilities. Antibiotic therapy should be continued until features of sepsis have resolved and surgery is completed. Patients may require repeated surgery until debridement and drainage are complete and healing has commenced.

### Special Considerations

Immunocompromised patients are more prone to SSTIs and may not demonstrate classic clinical features and laboratory findings because of their attenuated inflammatory response. Diagnostic testing should be performed early to identify the causative organism and evaluate the extent of involvement, and antibiotic therapy should be commenced to cover possible pathogens, including atypical organisms that can cause serious infections (e.g., resistant gram-negative bacteria, anaerobes, fungi).

Specific types of SSTIs may result from identifiable exposures. Dog and cat bites in an immunocompromised host and those that involve the face or hand, periosteum, or joint capsule are typically treated with a beta-lactam antibiotic or beta-lactamase inhibitor (e.g., amoxicillin/clavulanate [Augmentin]). In patients allergic to penicillin, a combination of trimethoprim/sulfamethoxazole or a quinolone with clindamycin or metronidazole (Flagyl) can be used. A recent article in *American Family Physician* provides further details about

### Inpatient Management of a Patient with Skin and Soft Tissue Infection

Patient presents with severe or uncontrolled infection despite outpatient antibiotics and drainage
Patient is septic, dehydrated, acidic, or immunosuppressed
Patient has organ dysfunction
Appropriate follow-up is unavailable
(Laboratory Risk Indicator for Necrotizing Fasciitis score ≥ 8; class 4, 3, and some class 2 infections [Tables 1 and 4])

**Inpatient management**

Complete blood count, C-reactive protein testing, liver and kidney function testing
Blood culture for severe infection and in immunocompromised or older patients
Culture of aspirate from advancing edge of cellulitis or abscess
Imaging for suspected necrotizing fasciitis or if no response to initial treatment of cellulitis or abscess
Tissue biopsy from advancing edge of cellulitis after debridement of bites or necrotizing fasciitis

Correction of fluid/electrolyte/acid-base imbalance
Empiric broad-spectrum antibiotics followed by culture-specific narrow-spectrum agents (include MRSA coverage; Tables 5 and 6)

Is surgical consultation required? (Purulence or suspected necrotizing fasciitis, gas gangrene, or deep bites involving joint?)

**Culture-specific antibiotics for 7 to 14 days; change to oral agents if clinical improvement is noted and oral administration is tolerated**

Abscess: incision and drainage, continue antimicrobials active against MRSA
Necrotizing fasciitis: debridement, continue polymicrobial coverage
Bites, gas gangrene: debridement, antimicrobials (Tables 5 and 6)
Change to oral agents if clinical improvement is noted, oral administration is tolerated, and drainage/debridement is complete
Total antibiotic course is 7 to 14 days, or 6 weeks if joint is involved

**Yes**

**No**
prophylaxis in patients with cat or dog bites (http://www.aafp.org/afp/2014/0815/p239.html).57

Simple SSTIs that result from exposure to fresh water are treated empirically with a quinolone, whereas doxycycline is used for those that occur after exposure to salt water. The choice is based on the presumptive infecting organisms (e.g., *Aeromonas hydrophila*, *Vibrio vulnificus*, *Mycobacterium marinum*).5

In patients with at least one prior episode of cellulitis, administering prophylactic oral penicillin, 250 mg twice

### Table 6. Antibiotic Choices for Necrotizing and Other Complicated Skin and Soft Tissue Infections in Adults and Children

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbapenems (ertapenem [Invanz], imipenem/cilastatin [Primaxin], meropenem [Merrem IV])</td>
<td>For polymicrobial necrotizing infections; safety of imipenem/cilastatin in children younger than 12 years is not known</td>
</tr>
<tr>
<td>Cefotaxime (Claforan)</td>
<td>Used with metronidazole (Flagyl) or clindamycin for initial treatment of polymicrobial necrotizing infections</td>
</tr>
<tr>
<td>Ceftaroline (Teflaro)</td>
<td>Dose adjustment required in patients with renal impairment; 5- to 14-day course</td>
</tr>
<tr>
<td>Ceftriaxone (Rocephin)</td>
<td>Useful in waterborne infections; used with doxycycline for <em>Aeromonas hydrophila</em> and <em>Vibrio vulnificus</em> infections</td>
</tr>
<tr>
<td>Dalbavancin (Dalvance)</td>
<td>For MSSA and MRSA infections; 2 doses, 1 week apart</td>
</tr>
<tr>
<td>Dalfopristin/quinupristin (Synercid)</td>
<td>For complicated MSSA and MRSA infections, especially in neutropenic patients and vancomycin-resistant infections</td>
</tr>
<tr>
<td>Daptomycin (Cubicin)</td>
<td>For MRSA infections; 7- to 14-day course in adults</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>Useful in waterborne infections; used with ciprofloxacin (Cipro), ceftriaxone, or cefotaxime in <em>A. hydrophila</em> and <em>V. vulnificus</em> infections</td>
</tr>
<tr>
<td>Linezolid (Zyvox)</td>
<td>For MRSA infections; oral or intravenous dosing; 7- to 14-day course in adults; 10- to 14-day course in children</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>Used with cefotaxime for initial treatment of polymicrobial necrotizing infections</td>
</tr>
<tr>
<td>Oritavancin (Orbactiv)</td>
<td>For MSSA, MRSA, and <em>Enterococcus faecalis</em> infections</td>
</tr>
<tr>
<td>Oxacillin or nafcillin</td>
<td>For necrotizing fasciitis caused by sensitive staphylococci</td>
</tr>
<tr>
<td>Penicillin plus clindamycin</td>
<td>Combined therapy for necrotizing fasciitis caused by streptococci; either drug is effective in clostridial infections</td>
</tr>
<tr>
<td>Piperacillin/tazobactam (Zosyn)</td>
<td>First-line antimicrobial for treating polymicrobial necrotizing infections</td>
</tr>
<tr>
<td>Telavancin (Vibativ)</td>
<td>For MSSA and MRSA infections; 7- to 14-day course; women of childbearing age should use 2 forms of birth control during treatment</td>
</tr>
<tr>
<td>Tigecycline (Tygacil)</td>
<td>For MRSA infections; 5- to 14-day course in adults; not recommended in children; increases mortality risk; considered medication of last resort</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>Parenteral drug of choice for MRSA infections in patients allergic to penicillin; 7- to 14-day course for skin and soft tissue infections; 6-week course for bacteremia; maintain trough levels at 10 to 20 mg per L</td>
</tr>
</tbody>
</table>

**Note:** This is a condensed version of this table. The full version is available online at http://www.aafp.org/afp.

MRSA = methicillin-resistant *Staphylococcus aureus*; MSSA = methicillin-sensitive *S. aureus*.

Information from references 5 and 27.
Skin and Soft Tissue Infections

SORT: KEY RECOMMENDATIONS FOR PRACTICE

<table>
<thead>
<tr>
<th>Clinical recommendation</th>
<th>Evidence rating</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood cultures seldom change treatment and are not required in healthy immunocompetent patients with SSTIs.</td>
<td>C</td>
<td>20</td>
</tr>
<tr>
<td>Uncomplicated purulent SSTIs in easily accessible areas without overlying cellulitis can be treated with incision and drainage only; antibiotic therapy does not improve outcomes.</td>
<td>C</td>
<td>29, 30</td>
</tr>
<tr>
<td>Inpatient treatment is recommended for patients with uncontrolled SSTIs despite adequate oral antibiotic therapy; those who cannot tolerate oral antibiotics; those who require surgery; those with initial severe or complicated SSTIs; and those with underlying unstable comorbid illnesses or signs of systemic sepsis.</td>
<td>C</td>
<td>3, 5</td>
</tr>
<tr>
<td>There is no evidence that any pathogen-sensitive antibiotic is superior to another in the treatment of MRSA SSTIs.</td>
<td>B</td>
<td>35</td>
</tr>
<tr>
<td>Treatment of necrotizing fasciitis involves early recognition and surgical debridement of necrotic tissue, combined with high-dose broad-spectrum intravenous antibiotics.</td>
<td>C</td>
<td>5</td>
</tr>
</tbody>
</table>

MRSA = methicillin-resistant Staphylococcus aureus; SSTI = skin and soft tissue infection.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.

daily for six months, reduces the risk of recurrence for up to three years by 47%. 38

Data Sources: A PubMed search was completed using the key term skin and soft tissue infections. The search included systematic reviews, meta-analyses, reviews of clinical trials and other primary sources, and evidence-based guidelines. Also searched were the Cochrane database, the National Institute for Health and Care Excellence guidelines, and Essential Evidence Plus. Search dates: May 7, 2014, through May 27, 2015.

The Authors

KALYANAKRISHNAN RAMAKRISHNAN, MD, is a professor of family and preventive medicine at the University of Oklahoma Health Sciences Center in Oklahoma City.

ROBERT C. SALINAS, MD, is an associate professor of family and preventive medicine at the University of Oklahoma Health Sciences Center.

NELSON IVAN AGUDELO HIGUITA, MD, is an assistant professor of infectious disease in the Internal Medicine Division at the University of Oklahoma Health Sciences Center.

Address correspondence to Kalyanakrishnan Ramakrishnan, MD, OUHSC, 900 NE 10th St., Oklahoma City, OK 73104 (e-mail: kramakrishnan@ouhsc.edu). Reprints are not available from the authors.

REFERENCES


### Table 5. Antibiotic Choices for Mild to Moderate Skin and Soft Tissue Infections in Adults and Children

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Amoxicillin/ clavulanate (Augmentin)| Adults: 500 mg orally 2 times per day or 250 mg orally 3 times per day  
Children younger than 3 months and less than 40 kg (89 lb): 25 to 45 mg per kg per day (amoxicillin component), divided every 12 hours  
Children older than 3 months and 40 kg or more: 30 mg per kg per day, divided every 12 hours | For impetigo; human or animal bites; and MSSA, *Escherichia coli* or *Klebsiella* infections  
Common adverse effects: diaper rash, diarrhea, nausea, vaginal mycosis, vomiting  
Rare adverse effects: agranulocytosis, hepatorenal dysfunction, hypersensitivity reactions, pseudomembranous enterocolitis |
| Cefazolin*                          | Adults: 250 to 500 mg IV or IM every 8 hours (500 to 1,500 mg IV or IM every 6 to 8 hours for moderate to severe infections)  
Children: 25 to 100 mg per kg per day IV or IM in 3 or 4 divided doses | For MSSA infections and human or animal bites  
Common adverse effects: diarrhea, drug-induced eosinophilia, pruritus  
Rare adverse effects: anaphylaxis, colitis, encephalopathy, renal failure, seizure, Stevens-Johnson syndrome |
| Cephalexin (Keflex)                 | Adults: 500 mg orally 4 times per day  
Children: 25 to 50 mg per kg per day in 2 divided doses | For MSSA infections, impetigo, and human or animal bites; twice-daily dosing is an option  
Common adverse effect: diarrhea  
Rare adverse effects: anaphylaxis, angioedema, interstitial nephritis, pseudomembranous enterocolitis |
| Clindamycin*                        | Adults: 150 to 450 mg orally 4 times per day (300 to 450 mg orally 4 times per day for 5 to 10 days for MRSA infection; 600 mg orally or IV 3 times per day for 7 to 14 days for complicated infections)  
Children: 16 mg per kg per day in 3 or 4 divided doses (16 to 20 mg per kg per day for more severe infections; 40 mg per kg per day in 3 or 4 divided doses for MRSA infection) | For impetigo; MSSA, MRSA, and clostridial infections; and human or animal bites  
Common adverse effects: abdominal pain, diarrhea, nausea, rash  
Rare adverse effects: agranulocytosis, elevated liver enzyme levels, erythema multiforme, jaundice, pseudomembranous enterocolitis |
| Dicloxacillin                        | Adults: 125 to 500 mg orally every 6 hours (maximal dosage, 2 g per day)  
Children less than 40 kg: 12.5 to 50 mg per kg per day divided every 6 hours  
Children 40 kg or more: 125 to 500 mg every 6 hours | For MSSA infections  
Common adverse effects: diarrhea, impetigo, nausea, vomiting  
Rare adverse effects: anaphylaxis, hemorrhagic colitis, hepatorenal toxicity |
| Doxycycline or minocycline (Minocin)| Adults: 100 mg orally 2 times per day  
Children 8 years and older and less than 45 kg (100 lb): 4 mg per kg per day in 2 divided doses  
Children 8 years and older and 45 kg or more: 100 mg orally 2 times per day | For MRSA infections and human or animal bites; not recommended for children younger than 8 years  
Common adverse effects: myalgia, photosensitivity  
Rare adverse effects: *Clostridium difficile* colitis, hepatotoxicity, pseudotumor cerebri, Stevens-Johnson syndrome |
| Fluoroquinolones                    | Adults: ciprofloxacin (Cipro), 500 to 750 mg orally 2 times per day or 400 mg IV 2 times per day; gatifloxacin or moxifloxacin (Avelox), 400 mg orally or IV per day | For human or animal bites; not useful in MRSA infections; not recommended for children  
Common adverse effects: diarrhea, headache, nausea, rash, vomiting  
Rare adverse effects: agranulocytosis, arrhythmias, hepatorenal failure, tendon rupture |

*IM = intramuscularly; IV = intravenously; MRSA = methicillin-resistant *Staphylococcus aureus*; MSSA = methicillin-sensitive *S. aureus*.  
*—Higher dosages used in complicated infections caused by sensitive organisms.  
Information from references 5 and 27.
**Table 5. Antibiotic Choices for Mild to Moderate Skin and Soft Tissue Infections in Adults and Children** (continued)

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mupirocin (Bactroban)*</td>
<td>2% ointment applied 3 times per day for 3 to 5 days</td>
<td>For MRSA impetigo and folliculitis; not recommended for children younger than 2 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rare adverse effects: burning over application site, pruritus</td>
</tr>
<tr>
<td>Retapamulin (Altabax)*</td>
<td>1% ointment applied 2 times per day for 5 days</td>
<td>For MSSA impetigo; not recommended for children younger than 9 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rare adverse effects: allergy, angioedema, application site irritation</td>
</tr>
<tr>
<td>Trimethoprim/</td>
<td>Adults: 1 or 2 double-strength tablets 2 times per day Children: 8 to 12 mg per kg per day (trimethoprim component) orally in 2 divided doses or IV in 4 divided doses</td>
<td>For MRSA infections and human or animal bites; contraindicated in children younger than 2 months</td>
</tr>
<tr>
<td>sulfamethoxazole</td>
<td></td>
<td>Common adverse effects: anorexia, nausea, rash, urticaria, vomiting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rare adverse effects: agranulocytosis, C. difficile colitis, erythema multiforme, hepatic necrosis, hyponatremia, rhabdomyolysis, Stevens-Johnson syndrome</td>
</tr>
</tbody>
</table>

*IM = intramuscularly; IV = intravenously; MRSA = methicillin-resistant Staphylococcus aureus; MSSA = methicillin-sensitive S. aureus.

*—Higher dosages used in complicated infections caused by sensitive organisms.

Information from references 5 and 27.
### Table 6. Antibiotic Choices for Necrotizing and Other Complicated Skin and Soft Tissue Infections in Adults and Children

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Carbapenems</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ertapenem (Invanz)</td>
<td>Adults: 1 g IV per day</td>
<td>For polymicrobial necrotizing infections; safety of imipenem/cilastatin in children younger than 12 years is not known</td>
</tr>
<tr>
<td></td>
<td>Children 3 months to 12 years: 15 mg per kg IV every 12 hours, up to 1 g per day</td>
<td>Common adverse effects: anemia, constipation, diarrhea, headache, injection site pain and inflammation, nausea, vomiting</td>
</tr>
<tr>
<td></td>
<td>Adults: 1 g IV every 6 to 8 hours</td>
<td>Rare adverse effects: acute coronary syndrome, angioedema, bleeding, <em>Clostridium difficile</em> colitis, congestive heart failure, hepatorenal failure, respiratory failure, seizures, vaginitis</td>
</tr>
<tr>
<td></td>
<td>Children: 25 mg per kg IV every 6 to 12 hours, up to 4 g per day</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adults: 1 g IV every 8 hours</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Children: 10 mg per kg (up to 500 mg) IV every 8 hours; increase to 20 mg per kg (up to 1 g) IV every 8 hours for <em>Pseudomonas</em> infections</td>
<td></td>
</tr>
<tr>
<td><strong>Ertapenem (Invanz)</strong></td>
<td>Adults: 1 g IV per day</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Children 3 months to 12 years: 15 mg per kg IV every 12 hours, up to 1 g per day</td>
<td></td>
</tr>
<tr>
<td><strong>Imipenem/cilastatin (Primaxin)</strong></td>
<td>Adults: 1 g IV every 6 to 8 hours</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Children: 25 mg per kg IV every 6 to 12 hours, up to 4 g per day</td>
<td></td>
</tr>
<tr>
<td><strong>Meropenem (Merrem IV)</strong></td>
<td>Adults: 1 g IV every 8 hours</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Children: 10 mg per kg (up to 500 mg) IV every 8 hours; increase to 20 mg per kg (up to 1 g) IV every 8 hours for <em>Pseudomonas</em> infections</td>
<td></td>
</tr>
<tr>
<td><strong>Cefotaxime (Claforan)</strong></td>
<td>Adults: 2 g IV every 6 hours</td>
<td>Used with metronidazole (Flagyl) or clindamycin for initial treatment of polymicrobial necrotizing infections</td>
</tr>
<tr>
<td></td>
<td>Children: 50 mg per kg IV every 6 hours</td>
<td>Common adverse effects: diarrhea, pain and thrombophlebitis at injection site, vomiting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rare adverse effects: agranulocytosis, arrhythmias, erythema multiforme</td>
</tr>
<tr>
<td><strong>Ceftaroline (Teflaro)</strong></td>
<td>Adults: 600 mg IV every 12 hours for 5 to 14 days</td>
<td>Dose adjustment required in patients with renal impairment</td>
</tr>
<tr>
<td></td>
<td>Unknown safety in children</td>
<td>Rare adverse effects: abdominal pain, arrhythmias, <em>C. difficile</em> colitis, diarrhea, dizziness, fever, hepatitis, rash, renal insufficiency, seizures, thrombophlebitis, urticaria, vomiting</td>
</tr>
<tr>
<td><strong>Ceftriaxone (Rocephin)</strong></td>
<td>Adults: 1 to 2 g IV every 24 hours</td>
<td>Useful in waterborne infections; used with doxycycline for <em>Aeromonas hydrophila</em> and <em>Vibrio vulnificus</em> infections</td>
</tr>
<tr>
<td></td>
<td>Children: 50 to 75 mg per kg IV or IM once per day or divided every 12 hours, up to 2 g per day</td>
<td>Common adverse effects: diarrhea, elevated platelet levels, eosinophilia, induration at injection site</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rare adverse effects: <em>C. difficile</em> colitis, erythema multiforme, hemolytic anemia, hyperbilirubinemia in newborns, pulmonary injury, renal failure</td>
</tr>
<tr>
<td><strong>Dalbavancin (Dalvance)</strong></td>
<td>Adults: 1,000 mg IV initial dose, followed by 500 mg IV 1 week later</td>
<td>For MSSA and MRSA infections</td>
</tr>
<tr>
<td></td>
<td>Not recommended in children</td>
<td>Common adverse effects: constipation, diarrhea, headache, nausea, nausea, pain, rash, vomiting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rare adverse effects: <em>C. difficile</em> colitis, gastrointestinal hemorrhage, hepatotoxicity, infusion reaction</td>
</tr>
<tr>
<td><strong>Dalbopristin/quinupristin (Synercid)</strong></td>
<td>Adults and children 12 years and older: 7.5 mg per kg IV every 12 hours</td>
<td>For complicated MSSA and MRSA infections, especially in neutropenic patients and vancomycin-resistant infections</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Common adverse effects: arthralgia, diarrhea, edema, hyperbilirubinemia, inflammation at injection site, myalgia, nausea, pain, rash, vomiting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rare adverse effects: arrhythmias, cerebrovascular events, encephalopathy, hemolytic anemia, hepatitis, myocardial infarction, pancytopenia, syncope</td>
</tr>
</tbody>
</table>

*IM = intramuscularly; IV = intravenously; MRSA = methicillin-resistant *Staphylococcus aureus*; MSSA = methicillin-sensitive *S. aureus.*

Information from references 5 and 27.
### Table 6. Antibiotic Choices for Necrotizing and Other Complicated Skin and Soft Tissue Infections in Adults and Children (continued)

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daptomycin (Cubicin)</td>
<td>Adults: 4 mg per kg IV per day for 7 to 14 days  Not recommended in children</td>
<td>For MRSA infections  Common adverse effects: diarrhea, throat pain, vomiting  Rare adverse effects: gram-negative infections, pulmonary eosinophilia, renal failure, rhabdomyolysis</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>Adults: 100 mg IV every 12 hours  Children 8 years and older and less than 45 kg (100 lb): 4 mg per kg IV per day in 2 divided doses  Children 8 years and older and 45 kg or more: 100 mg IV every 12 hours</td>
<td>Useful in waterborne infections; used with ciprofloxacin (Cipro), ceftriaxone, or cefotaxime in <em>A. hydrophila</em> and <em>V. vulnificus</em> infections  Common adverse effects: diarrhea, photosensitivity  Rare adverse effects: <em>C. difficile</em> colitis, erythema multiforme, liver toxicity, pseudotumor cerebri</td>
</tr>
<tr>
<td>Linezolid (Zyvox)</td>
<td>Adults: 600 mg IV or orally every 12 hours for 7 to 14 days  Children 12 years and older: 600 mg IV or orally every 12 hours for 10 to 14 days  Children younger than 12 years: 10 mg per kg IV or orally every 8 hours for 10 to 14 days</td>
<td>For MRSA infections  Common adverse effects: diarrhea, headache, nausea, vomiting  Rare adverse effects: <em>C. difficile</em> colitis, hepatic injury, lactic acidosis, myelosuppression, optic neuritis, peripheral neuropathy, seizures</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>Adults: 600 to 900 mg IV every 8 hours  Children: 10 to 13 mg per kg IV every 8 hours</td>
<td>Used with cefotaxime for initial treatment of polymicrobial necrotizing infections  Common adverse effects: abdominal pain, altered taste, diarrhea, dizziness, headache, nausea, vaginitis  Rare adverse effects: aseptic meningitis, encephalopathy, hemolytic-uremic syndrome, leukopenia, optic neuropathy, ototoxicity, peripheral neuropathy, Stevens-Johnson syndrome</td>
</tr>
<tr>
<td>Oritavancin (Orbactiv)</td>
<td>Adults: 1,200-mg infusion over 3 hours  Not indicated in children</td>
<td>For MSSA, MRSA, and <em>Enterococcus faecalis</em> infections  Common adverse effects: headache, nausea, vomiting  Rare adverse effects: <em>C. difficile</em> colitis, clotting abnormalities, hypersensitivity, infusion complications (thrombophlebitis), osteomyelitis</td>
</tr>
<tr>
<td>Oxacillin or nafcillin</td>
<td>Adults: 1 to 2 g IV every 4 hours  Children: 25 mg per kg IM 2 times per day</td>
<td>For necrotizing fasciitis caused by sensitive staphylococci  Rare adverse effects: anaphylaxis, bone marrow suppression, hypokalemia, interstitial nephritis, pseudomembranous enterocolitis</td>
</tr>
</tbody>
</table>
| Penicillin plus clindamycin | Adults: 2 to 4 million units penicillin IV every 6 hours plus 600 to 900 mg clindamycin IV every 8 hours  Children: 60,000 to 100,000 units penicillin per kg IV every 6 hours plus 10 to 13 mg clindamycin per kg IV per day in 3 divided doses  For MRSA infections in children: 40 mg per kg IV per day in 3 or 4 divided doses | Combined therapy for necrotizing fasciitis caused by streptococci; either drug is effective in clostridial infections  Adverse effects from penicillin are rare in nonallergic patients  Common adverse effects of clindamycin: abdominal pain, diarrhea, nausea, rash  Rare adverse effects of clindamycin: agranulocytosis, elevated liver enzyme levels, erythema multiforme, jaundice, pseudomembranous enterocolitis  

IM = intramuscularly; IV = intravenously; MRSA = methicillin-resistant *Staphylococcus aureus*; MSSA = methicillin-sensitive *S. aureus*.  

*Information from references 5 and 27.*
### Table 6. Antibiotic Choices for Necrotizing and Other Complicated Skin and Soft Tissue Infections in Adults and Children (continued)

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Dosage</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Piperacillin/tazobactam (Zosyn)   | Adults: 3.375 g IV every 6 to 8 hours  
Children: 60 to 75 mg per kg (piperacillin component) IV every 6 hours | First-line antimicrobial for treating polymicrobial necrotizing infections  
Common adverse effects: constipation, diarrhea, fever, headache, insomnia, nausea, pruritus, vomiting  
Rare adverse effects: agranulocytosis, *C. difficile* colitis, encephalopathy, hepatorenal failure, Stevens-Johnson syndrome |
| Telavancin (Vibativ)              | Adults: 10 mg per kg IV per day for 7 to 14 days  
Not recommended in children | For MSSA and MRSA infections; women of childbearing age should use 2 forms of birth control during treatment  
Common adverse effects: altered taste, nausea, vomiting  
Rare adverse effects: hypersensitivity, prolonged QT interval, renal insufficiency |
| Tigecycline (Tygacil)             | Adults: 100 mg IV followed by 50 mg IV every 12 hours for 5 to 14 days  
Not recommended in children | For MRSA infections; increases mortality risk; considered medication of last resort  
Common adverse effects: abdominal pain, diarrhea, nausea, vomiting  
Rare adverse effects: anaphylaxis, *C. difficile* colitis, liver dysfunction, pancreatitis, pseudotumor cerebri, septic shock |
| Vancomycin                        | Adults: 15 mg per kg IV every 12 hours  
Children: 10 mg per kg IV every 6 hours | Parenteral drug of choice for MRSA infections in patients allergic to penicillin; 7- to 14-day course for skin and soft tissue infections; 6-week course for bacteremia; maintain trough levels at 10 to 20 mg per L  
Common adverse effects: abdominal pain, diarrhea, nausea, vomiting  
Rare adverse effects: agranulocytosis, anaphylaxis, *C. difficile* colitis, hypotension, nephrotoxicity, ototoxicity |

IM = intramuscularly; IV = intravenously; MRSA = methicillin-resistant *Staphylococcus aureus*; MSSA = methicillin-sensitive *S. aureus*.

Information from references 5 and 27.